M&A battle intensifies: Pfizer and Novo Nordisk in multi-billion dollar bid for "weight-loss rising star" Metsera

``` On Monday, the U.S. market saw four major deals announced in a single day with a total value exceeding $80 billion, pushing this year’s M&A frenzy to a new high. In this context, the bidding war between pharmaceutical giants Pfizer and Novo Nordisk for the “weight-loss drug upstart” Metsera has also reached a fever pitch. According to the UK Financial Times citing two people familiar with the matter, Pfizer submitted a new bid before Wednesday's deadline, raising its offer to match Novo Nordisk’s: $86.20 per share, with a total price of up to $10 billion. This move allows Pfizer to remain at the negotiating table. Previously, Metsera’s board had determined that its Danish competitor Novo Nordisk’s offer was superior. Pfizer and Novo Nordisk are fiercely competing for the acquisition of this biotech company with a promising pipeline. This latest development quickly ignited market sentiment. After news broke that Pfizer was matching the bid, Metsera’s share price rose as much as 8% in after-hours trading, exceeding $77 per share. Key Battle on a Billion-Dollar Track At the core of this acquisition war is Metsera’s promising weight-loss drug pipeline, including a once-monthly injectable that could be a market game-changer. In a market currently dominated by Novo Nordisk’s Ozempic and Eli Lilly, any company able to provide a more convenient and effective therapeutic option could gain a huge competitive advantage. For Novo Nordisk, acquiring Metsera is a defensive move to solidify its market leadership. For Pfizer, it’s a critical offensive push aimed at quickly entering this golden sector, which is expected to exceed a $100 billion market size by the end of this century. Winning Metsera means securing a valuable strategic chip in future market competition. A Bidding Process Full of Twists and Turns The bidding war has been full of dramatic twists. Initially, Pfizer had reached a preliminary agreement with Metsera in September. But last week, Novo Nordisk suddenly launched a public, non-binding offer in an attempt to “break into” the deal, sparking an intense bidding contest. It’s reported that both parties raised their bids this Tuesday. Novo Nordisk’s offer included a $62.20 per share upfront payment and $24 in subsequent milestone payments, a total of $86.20 per share, which Metsera’s board deemed the “superior offer.” At that time, Pfizer’s offer was $70 per share, valuing Metsera at about $8.1 billion. Just a day later, Pfizer quickly raised its bid to match Novo Nordisk’s. Under the merger agreement, if Novo Nordisk again raises its offer, Pfizer will have two days to decide whether to match. A shareholder vote on the deal is scheduled for November 13. Dual Tests of Legal and Regulatory Scrutiny Beyond the commercial bids, legal and regulatory battles are equally intense. Pfizer has filed a lawsuit, accusing Novo Nordisk’s “two-step” payment structure—designed to circumvent antitrust review—of being “unprecedented and illegal.” Although Pfizer suffered a setback at Wednesday’s hearing, it stated that it will “vigorously pursue its claims through ongoing litigation and the parallel antitrust lawsuit pending in U.S. federal court in Delaware.” Regulatory agency intervention has further complicated the situation. The FTC has sent letters to Novo Nordisk and Metsera, warning that their deal structure “may violate” competition law. Novo Nordisk responded that it is in “constructive dialogue” with the FTC and believes its proposal complies with antitrust rules. Pfizer welcomed the regulators’ intervention, stating that they “have also expressed serious concerns.” A Reflection of the Global M&A Boom The battle between Pfizer and Novo Nordisk over Metsera is a microcosm of the current strong rebound in the global M&A market. According to Wallstreetcn, data shows that global M&A volume so far this year has reached $3.8 trillion, a year-on-year increase of about 38%. Companies are actively taking advantage of this window period to reshape industry patterns through transformative strategic acquisitions. From AI infrastructure to biotech, major deals are frequent, reflecting capital’s fervent pursuit of high-growth-potential sectors. Risk Disclosure and Disclaimer The market involves risk, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article fit their particular situation. Investment based on this information is at your own risk. ```